MARKET

GILD

GILD

Gilead Sciences
NASDAQ

Real-time Quotes | Nasdaq Last Sale

70.96
-0.65
-0.91%
After Hours: 70.95 -0.01 -0.01% 19:59 09/20 EDT
OPEN
70.93
PREV CLOSE
71.61
HIGH
71.92
LOW
70.33
VOLUME
9.59M
TURNOVER
--
52 WEEK HIGH
73.34
52 WEEK LOW
56.56
MARKET CAP
88.97B
P/E (TTM)
17.42
1D
5D
1M
3M
1Y
5Y
Global Immunotherapy Drugs Market Report Analysis, Share, Revenue, Growth Rate With Forecast Overview 2029
Research Nester published a report titled which delivers detailed overview of the global immunotherapy drugs market in terms of market segmentation by type, therapy area, and by region.
AmericaNewsHour · 9h ago
3 Value Stocks to Buy While You Still Can
Investor Place · 10h ago
Gilead To Present Latest Antiviral Research Data Addressing Urgent Global Needs In Infectious Disease At IDWeek 2021
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the upcoming presentation of new data from the company’s virology research and development programs at the virtual IDWeek 2021 conference, taking place September
Benzinga · 11h ago
BRIEF-Gilead Sciences Inc To Present Antiviral Research Data Infectious Disease At Idweek 2021
reuters.com · 11h ago
Global Diverticulitis Drugs Market Increasing Gastrointestinal Diseases to Create Growth Opportunities for the Market till 2029
Research Nester published a report titled "" which delivers detailed overview of the global diverticulitis drugs market in terms of market segmentation by drug type, route of administration, distribution channel, end-user and by region.
AmericaNewsHour · 14h ago
Barron's Latest Picks And Pans: Apple, Bitcoin, a Goldman Sachs ETF, Nike And More
This weekend's Barron's cover story examines the threats and opportunities as currencies go digital.
Benzinga · 2d ago
Baidu, Gilead Sciences And Nvidia Stocks Provide Plays For Both Bulls And Bears: Here's How
Baidu.
Benzinga · 3d ago
Gilead Churns Out Additional Trodelvy Data
Benzinga · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GILD. Analyze the recent business situations of Gilead Sciences through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 28 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GILD stock price target is 75.84 with a high estimate of 100.00 and a low estimate of 63.00.
EPS
Institutional Holdings
Institutions: 2.19K
Institutional Holdings: 1.07B
% Owned: 85.73%
Shares Outstanding: 1.25B
TypeInstitutionsShares
Increased
632
51.80M
New
104
12.72M
Decreased
559
35.89M
Sold Out
113
7.44M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/Chief Executive Officer/Director
Daniel O'Day
Chief Financial Officer
Andrew Dickinson
Executive Vice President/General Counsel/Secretary
Brett Pletcher
Executive Vice President
Flavius Martin
Other
Johanna Mercier
Other
Merdad Parsey
Lead Director/Independent Director
Kevin Lofton
Independent Director
Jacqueline Barton
Independent Director
Jeffrey Bluestone
Independent Director
Sandra Horning
Independent Director
Kelly Kramer
Independent Director
Harish Manwani
Independent Director
Javier Rodriguez
Independent Director
Anthony Welters
Declaration Date
Dividend Per Share
Ex-Div Date
07/29/2021
Dividend USD 0.71
09/14/2021
04/27/2021
Dividend USD 0.71
06/14/2021
02/04/2021
Dividend USD 0.71
03/12/2021
10/28/2020
Dividend USD 0.68
12/14/2020
07/30/2020
Dividend USD 0.68
09/14/2020
04/29/2020
Dividend USD 0.68
06/11/2020
02/03/2020
Dividend USD 0.68
03/12/2020
10/23/2019
Dividend USD 0.63
12/12/2019
07/29/2019
Dividend USD 0.63
09/12/2019
05/01/2019
Dividend USD 0.63
06/13/2019
02/01/2019
Dividend USD 0.63
03/14/2019
10/24/2018
Dividend USD 0.57
12/13/2018
07/24/2018
Dividend USD 0.57
09/13/2018
04/30/2018
Dividend USD 0.57
06/14/2018
02/05/2018
Dividend USD 0.57
03/15/2018
10/25/2017
Dividend USD 0.52
12/14/2017
07/25/2017
Dividend USD 0.52
09/14/2017
05/01/2017
Dividend USD 0.52
06/14/2017
02/06/2017
Dividend USD 0.52
03/14/2017
10/31/2016
Dividend USD 0.47
12/13/2016
  • All
  • Financials
  • Insiders
More
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.

Webull offers kinds of Gilead Sciences, Inc. stock information, including NASDAQ:GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.